This version of the registration was submitted prior to the Lobbying Transparency Act coming into force on May 4, 2020. Due to different information requirements at that time, the registration is presented in the following format.
Registration ID: 993928 Submitted by lobbyist on: June 27, 2019 11:29:02 AM Accepted by Registrar on: June 27, 2019 01:16:29 PM
Designated Filer Information
Keon, James J
4100 Yonge Street Suite 501
Toronto, ON, M2P 2B5
416-223-2333
Canada
Organization Information
Canadian Generic Pharmaceutical Association (CGPA)
The CGPA's mission is to promote an environment which supports and enhances the provision of affordable generic medications to Canadians and patients around the world. The Association researches and develops positions regarding a wide variety of policies, regulations and legislation that affects our member companies. We promote our sector's interests by publishing material as well as directly contacting government officials, the media and other opinion leaders and decision makers.
4120 Yonge Street Suite 501
Toronto, BC, M2P 2B5
416-223-2333
Canada
Relevant Affiliates
The client has no relevant affiliates.
Government or Government Agency Funding
The organization does not receive any funding from a government or government agency.
Other Controlling or Directing Interests
The organization has no other controlling or directing interests.
Active Registration Period
June 27, 2019
December 27, 2019
Organization's In-House Lobbyists
Name:
Connell, Jeff
June 27, 2019
Inactivation Date:
January 20, 2020
BC Public Office Background
This individual has not held any public office positions in BC.
Lobbying Activities
Health
Awarding, amendment or termination of a contract, grant or financial benefit
Development, establishment, amendment or termination of any program, policy or decision
Developing a regulatory pathway for biosimilars. Addressing use of brand coupon cards. Protecting the interests of Canada's generic pharmaceutical industry during implementation of the Comprehensive Economic and Trade Agreement and the USMCA. Implementation of commitments made by British Columbia pursuant to its involvement with the pan-Canadian Pharmaceutical Alliance. Payment of distribution fees by the government. Promoting greater utilization of generic prescription medicines. Price increase policy. Scope of listings. National Pharmacare initiative.
Target Contacts
Target Type
Name
Title or Constituency
Date Added
Minister
Dix,
Adrian
Minister of Health
June 27, 2019
Staff of Minister
Singh,
Jasmyn
Minister of Health
June 27, 2019
Public Agency
Health
June 27, 2019
Name:
Cox, Jody
June 27, 2019
Inactivation Date:
January 20, 2020
BC Public Office Background
This individual has not held any public office positions in BC.
Lobbying Activities
Health
Awarding, amendment or termination of a contract, grant or financial benefit
Development, establishment, amendment or termination of any program, policy or decision
Developing a regulatory pathway for biosimilars. Protecting the interests of Canada's generic pharmaceutical industry during implementation of the Comprehensive Economic and Trade Agreement and the USMCA.
Target Contacts
Target Type
Name
Title or Constituency
Date Added
Minister
Dix,
Adrian
Minister of Health
June 27, 2019
Staff of Minister
Singh,
Jasmyn
Minister of Health
June 27, 2019
Public Agency
Health
June 27, 2019
Name:
Keon, James
June 27, 2019
Inactivation Date:
January 20, 2020
BC Public Office Background
This individual has not held any public office positions in BC.
Lobbying Activities
Health
Awarding, amendment or termination of a contract, grant or financial benefit
Development, establishment, amendment or termination of any program, policy or decision
Developing a regulatory pathway for biosimilars. Addressing use of brand coupon cards. Protecting the interests of Canada's generic pharmaceutical industry during implementation of the Comprehensive Economic and Trade Agreement and the USMCA. Implementation of commitments made by British Columbia pursuant to its involvement with the pan-Canadian Pharmaceutical Alliance. Payment of distribution fees by the government. Promoting greater utilization of generic prescription medicines. Price increase policy. Scope of listings. National Pharmacare initiative.
